Ann: Program Update Anagrelide, page-18

I’m not sure Buckland how easy zolpi approval would be in Europe.

Years ago Rechon, who manufacture zolpi in Sweden, took the non-US rights from Novadel. After a year or two they gave up on it and the rights reverted back to Novadel. So given Rechon manufactured zolpi most likely the problem they ran in to was approvals.

Anyway zolpi might be quite a good business opportunity for shareholders. According to Novadel the patent for zolpi was due to expire in 2018.

https://www.businesswire.com/news/home/20091105005625/en/NovaDel-Receives-Notice-Allowance-New-U.S.-Patent

And the US patent office shows the zolpi patent has in fact expired.

So shareholders cut out the SUD middleman and get the approval in Australia yourselves. Order a crate from Rechon and present a complementary bottle to SUD at the AGM. It might lighten up the mood a bit.